Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer.

To identify the risk factors and attributable mortality associated with superinfections in febrile neutropenic patients with hematologic malignancies, we prospectively evaluated 333 episodes of fever and neutropenia by means of univariate and multivariate analyses. Superinfection was defined as any infection either occurring during antibiotic therapy or developing within 1 week after discontinuation of antibiotic therapy. Of 333 episodes, 46 (13.8%) were defined as superinfection; these episodes occurred in 46 patients. The risk factors for superinfection in the multivariate analysis were longer duration of profound neutropenia (P < .0001), lack of use of quinolones as prophylaxis (P < .0001), presence of a central venous catheter (P = .02), and persistence of fever after 3 days of antibiotic therapy (P = .02). The crude mortality rate among patients with superinfection was 48%, and the attributable mortality rate was 24% (95% confidence interval, 3%-45%). Identifying risk factors for superinfections in neutropenic patients might allow clinical practices to reduce the negative impact of this complication.

[1]  J. Romero-Vivas,et al.  Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Nucci,et al.  The treatment of acute myeloid leukemia in Brazil: progress and obstacles. , 1995, Haematologica.

[3]  M. Nucci,et al.  Quinolone prophylaxis in neutropenic patients - efficacy versus resistance. , 1994, Oncology reports.

[4]  H. Richet,et al.  Fluoroquinolone use and fluoroquinolone resistance: is there an association? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Nucci,et al.  Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients. , 1994, The Journal of infection.

[6]  T. Calandra,et al.  Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. , 1994, The New England journal of medicine.

[7]  G. Bodey Empirical antibiotic therapy for fever in neutropenic patients. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[9]  G. Bodey,et al.  Infectious complications of indwelling vascular catheters. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Anaissie,et al.  A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. , 1992, Archives of internal medicine.

[11]  Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1991, Annals of internal medicine.

[12]  R. Woolson,et al.  Risk factors for hospital-acquired candidemia. A matched case-control study. , 1989, Archives of internal medicine.

[13]  I. Dybedal,et al.  Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. , 1989, European journal of haematology.

[14]  R. Wenzel,et al.  The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? , 1988, International journal of epidemiology.

[15]  W. Schaffner,et al.  Frequency of broviac catheter infections in pediatric oncology patients. , 1986, The Journal of infectious diseases.

[16]  L. Elting,et al.  Aztreonam therapy in neutropenic patients with cancer. , 1986, The American journal of medicine.

[17]  J. Mcgowan,et al.  Antimicrobial resistance in hospital organisms and its relation to antibiotic use. , 1983, Reviews of infectious diseases.

[18]  C. Schiffer,et al.  Improved prognosis for granulocytopenic patients with gram-negative bacteremia. , 1980, The American journal of medicine.

[19]  P. Pizzo,et al.  Treatment of gram‐positive septicemia in cancer patients , 1980, Cancer.

[20]  R. Feld,et al.  β-Lactum antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients , 1976, The American journal of the medical sciences.